PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
12115607-2	2002	We previously reported aberrant high production of B lymphocyte chemoattractant (BLC/CXCL13) by DC in aged BWF1 mice, amurine model for systemic lupus erythematosus (SLE).	Amurine	118-125	WD repeat and FYVE domain containing 3	Mus musculus	107-111
1423777-2	1992	The results showed that MTX delayed the appearance of proteinuria and prolonged survival of both BWF1 and MRL/lpr mice and inhibited the elevation of blood urea nitrogen (BUN) levels which accompanies the development of lupus nephritis.	Methotrexate	24-27	WD repeat and FYVE domain containing 3	Mus musculus	97-101
12133425-2	2002	METHODS: Different doses of Tripterine were injected peritoneally to BW F1 mice at different stages.	celastrol	28-38	WD repeat and FYVE domain containing 3	Mus musculus	69-74
8933277-4	1996	The T cell clones from BWF1 mice but not those from BALB/c mice proliferated against heparan sulfate, the major glycosaminoglycan of glomerular basement membrane.	Heparitin Sulfate	85-100	WD repeat and FYVE domain containing 3	Mus musculus	23-27
8933277-9	1996	These studies indicate the existence of heparan sulfate-reactive T cells in BWF1 mice.	Heparitin Sulfate	40-55	WD repeat and FYVE domain containing 3	Mus musculus	76-80
1423777-5	1992	These suggest that the therapeutic effect of MTX on BWF1 and MRL/lpr mice does not result in the suppression of IgG autoantibody production.	Methotrexate	45-48	WD repeat and FYVE domain containing 3	Mus musculus	52-56
35470257-4	2022	In this study, we report a progressive reduction in TFR cells and decreased TFR/TFH ratio despite increased Tregs in the renal lymph nodes of NZBWF1/j mice, which correlated with increased GC-B cells and proteinuria onset.	tregs	108-113	WD repeat and FYVE domain containing 3	Mus musculus	142-148
34093553-3	2021	injection or oral administration of tolerogenic doses of pCons, an artificial synthetic peptide based on sequences containing MHC class I and MHC class II determinants in the VH region of a J558-encoded BWF1 anti-DNA Ab.	pcons	57-62	WD repeat and FYVE domain containing 3	Mus musculus	203-207
34187232-6	2021	Our results support and further extend Wdfy3"s role in modulating both brain bioenergetics and synaptic plasticity by including glycogen as a target of macroautophagic degradation.	Glycogen	128-136	WD repeat and FYVE domain containing 3	Mus musculus	39-44
35099014-5	2022	We show that ALFY localizes to RAB5 and EEA1 positive early endosomes in a PtdIns(3)P dependent manner and is highly enriched in cellular protrusions at the leading and lagging edge of migrating cells.	phosphatidylinositol 3-phosphate	75-85	WD repeat and FYVE domain containing 3	Mus musculus	13-17
2427544-7	1986	The BWF1 B cell lines were resistant to tolerance induction by DNP-MGG and required 50-fold higher dose of DNP-MGG than BALB/c cell lines for suppression.	dnp	63-66	WD repeat and FYVE domain containing 3	Mus musculus	4-8
35260898-0	2022	Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset.	Imiquimod	34-43	WD repeat and FYVE domain containing 3	Mus musculus	19-25
35260898-5	2022	Female and male NZBWF1 (BWF1) mice were treated from 20 weeks of age with a TLR7 agonist, imiquimod (IMQ), 3 times weekly for up to 12 weeks.	Imiquimod	90-99	WD repeat and FYVE domain containing 3	Mus musculus	16-22
35260898-6	2022	IMQ-exposed female BWF1 mice showed worsened lupus nephritis.	Imiquimod	0-3	WD repeat and FYVE domain containing 3	Mus musculus	19-23
35260898-9	2022	In IMQ-exposed BWF1 mice, neutralization of IFN-gamma suppressed early-phase lupus nephritis.	Imiquimod	3-6	WD repeat and FYVE domain containing 3	Mus musculus	15-19
35260898-10	2022	Additionally, in male BWF1 mice IMQ exposure induced minor aggravation of lupus nephritis.	Imiquimod	32-35	WD repeat and FYVE domain containing 3	Mus musculus	22-26
3219994-5	1988	PA derivatives suppressed adjuvant-induced arthritis in SD and Lewis rats, suppressed delayed-type hypersensitivity and IgE antibody response in mice, and prolonged the survival time of NZBXNZW F1 hybrid (BWF1) mice, as did immunosuppressors.	Penicillamine	0-2	WD repeat and FYVE domain containing 3	Mus musculus	205-209
2427544-7	1986	The BWF1 B cell lines were resistant to tolerance induction by DNP-MGG and required 50-fold higher dose of DNP-MGG than BALB/c cell lines for suppression.	dnp	107-110	WD repeat and FYVE domain containing 3	Mus musculus	4-8
34051810-0	2021	LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.	Cisplatin	26-35	WD repeat and FYVE domain containing 3	Mus musculus	7-12
6697574-1	1984	In this study, we examine the influence of the intravenous administration of nucleoside-coupled spleen cells on the spontaneous development of murine lupus nephritis in young and adult BWF1 mice.	Nucleosides	77-87	WD repeat and FYVE domain containing 3	Mus musculus	185-189
6697574-3	1984	Rather, in young mice administration of nucleoside-coupled spleen cells accelerates the appearance of anti-DNA antibody suggesting that BWF1 have a specific defect in the immunoregulation of anti-DNA antibody production.	Nucleosides	40-50	WD repeat and FYVE domain containing 3	Mus musculus	136-140
34051810-3	2021	Herein, we explored the function of lncRNA WDFY3-AS2 in OC cell resistance to cisplatin (DDP).	Cisplatin	78-87	WD repeat and FYVE domain containing 3	Mus musculus	43-48
34051810-3	2021	Herein, we explored the function of lncRNA WDFY3-AS2 in OC cell resistance to cisplatin (DDP).	Cisplatin	89-92	WD repeat and FYVE domain containing 3	Mus musculus	43-48
34051810-12	2021	Furthermore, xenograft tumor in nude mice was used to assess the impact of WDFY3-AS2 on cisplatin resistance in OC in vivo.	Cisplatin	88-97	WD repeat and FYVE domain containing 3	Mus musculus	75-80
34051810-17	2021	MiR-139-5p inhibitor or SDC4 overexpression could restore the suppressive influence of silenced WDFY3-AS2 on tumor growth.	mir-139-5p	0-10	WD repeat and FYVE domain containing 3	Mus musculus	96-101
34051810-18	2021	CONCLUSIONS: Together, WDFY3-AS2 may lead to change of cisplatin resistance by the expression of miR-139-5p/SDC4 in the OC A2870-DDP cells both in vitro and in vivo.	Cisplatin	55-64	WD repeat and FYVE domain containing 3	Mus musculus	23-28
33732257-2	2021	cSiO2"s autoimmune effects in humans can be mimicked chronically in female lupus-prone NZBWF1 mice following repeated exposure to the particle.	csio2	0-5	WD repeat and FYVE domain containing 3	Mus musculus	87-93
33897700-2	2021	Lupus triggering can be recapitulated in female NZBWF1 mice by four weekly intranasal instillations with 1 mg cSiO2.	csio2	110-115	WD repeat and FYVE domain containing 3	Mus musculus	48-54
33897700-6	2021	Here we tested the hypothesis that DHA intervention after cSiO2-initiated intrapulmonary autoimmunity will suppress lupus progression in the NZBWF1 mouse.	Docosahexaenoic Acids	35-38	WD repeat and FYVE domain containing 3	Mus musculus	141-147
33988501-7	2021	In mice, rapamycin treatment increases expression of histone proteins and Wdfy3 transcription, and alters chromatin organisation in the small intestine, suggesting the mTORC1-histone axis is at least partially conserved in mammals and may offer new targets for anti-ageing interventions.	Sirolimus	9-18	WD repeat and FYVE domain containing 3	Mus musculus	74-79
33931880-5	2021	KEY RESULTS: Antibiotic treatment inhibited the development of hypertension, renal injury, improved endothelial dysfunction and vascular oxidative stress, and decreased aortic helper T (Th)17 infiltration in NZBWF1 mice.	t (th)17	183-191	WD repeat and FYVE domain containing 3	Mus musculus	208-214
32903098-2	2020	Exposing lupus-prone NZBWF1 mice to respirable cSiO2 unleashes a vicious cycle of inflammation and cell death in the lung that triggers interferon-regulated gene expression, ectopic lymphoid structure (ELS) development, elevation of local and systemic autoantibodies (AAbs), and glomerulonephritis.	csio2	47-52	WD repeat and FYVE domain containing 3	Mus musculus	21-27
33559345-0	2021	Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells.	Camptothecin	0-12	WD repeat and FYVE domain containing 3	Mus musculus	127-133
33559345-0	2021	Camptothecin and topotecan, inhibitors of transcription factor Fli-1 and topoisomerase, markedly ameliorate lupus nephritis in NZBWF1 mice and reduce the production of inflammatory mediators in human renal cells.	Topotecan	17-26	WD repeat and FYVE domain containing 3	Mus musculus	127-133
33559345-1	2021	OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in NZBWF1 mice and their effects on inflammatory mediators in human renal cells.	Camptothecin	49-61	WD repeat and FYVE domain containing 3	Mus musculus	171-177
33559345-1	2021	OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in NZBWF1 mice and their effects on inflammatory mediators in human renal cells.	Topotecan	72-81	WD repeat and FYVE domain containing 3	Mus musculus	171-177
33559345-1	2021	OBJECTIVE: To examine the therapeutic effects of camptothecin (CPT) and topotecan (TPT), inhibitors of transcription factor Fli-1 and topoisomerase, on lupus nephritis in NZBWF1 mice and their effects on inflammatory mediators in human renal cells.	Topotecan	83-86	WD repeat and FYVE domain containing 3	Mus musculus	171-177
33123123-1	2020	Airway exposure of lupus-prone NZBWF1 mice to crystalline silica (cSiO2), a known trigger of human autoimmune disease, elicits sterile inflammation and alveolar macrophage death in the lung that, in turn, induces early autoimmune onset and accelerates lupus progression to fatal glomerulonephritis.	Silicon Dioxide	58-64	WD repeat and FYVE domain containing 3	Mus musculus	31-37
33123123-1	2020	Airway exposure of lupus-prone NZBWF1 mice to crystalline silica (cSiO2), a known trigger of human autoimmune disease, elicits sterile inflammation and alveolar macrophage death in the lung that, in turn, induces early autoimmune onset and accelerates lupus progression to fatal glomerulonephritis.	csio2	66-71	WD repeat and FYVE domain containing 3	Mus musculus	31-37
33015091-3	2020	We previously reported that in female NZBWF1 mice, a commonly used mouse model of SLE with a female sex bias, increased urinary transferrin excretion and renal iron accumulation occur around the onset of albuminuria.	Iron	160-164	WD repeat and FYVE domain containing 3	Mus musculus	38-44
31725357-2	2019	Using the NZBWF1 mouse, which spontaneously develops lupus, we found that intranasal exposure to cSiO2 significantly decreases latency and promotes rapid progression of the disease.	csio2	97-102	WD repeat and FYVE domain containing 3	Mus musculus	10-16
31820642-3	2020	Depleting androgens by castration dramatically increases the susceptibility of BWF1 male to lupus.	Androgens	10-19	WD repeat and FYVE domain containing 3	Mus musculus	79-83
30617186-0	2019	Sodium 4-phenylbutyrate treatment protects against renal injury in NZBWF1 mice.	4-phenylbutyric acid	0-23	WD repeat and FYVE domain containing 3	Mus musculus	67-73
30617186-3	2019	To investigate this, a small molecule chaperone, sodium 4-phenylbutyrate (4-PBA), was administered to the New Zealand Black x New Zealand White F1 hybrid (NZBWF1) mouse model of SLE.	4-phenylbutyric acid	49-72	WD repeat and FYVE domain containing 3	Mus musculus	155-161
30617186-4	2019	In a prevention study, treatment with 4-PBA from 20 weeks of age (prior to the development of renal injury) delayed the onset of albuminuria and significantly reduced additional indices of renal injury compared with vehicle-treated NZBWF1 mice at 36 weeks of age, including collagen deposition, tubular casts, renal cell apoptosis, and blood urea nitrogen (BUN) concentration.	4-phenylbutyric acid	38-43	WD repeat and FYVE domain containing 3	Mus musculus	232-238
23607366-4	2013	We found that iNK T cell in-vivo cytokine responses to an iNK T cell ligand alpha-galactosylceramide (alpha-GalCer) were lower in BWF(1) mice than in non-autoimmune BALB/c and major histocompatibility complex (MHC)-matched NZB x N/B10.PL F1 mice, although iNK T cell numbers in the periphery were unchanged in BWF(1) mice compared to control mice.	alpha-galactosylceramide	76-100	WD repeat and FYVE domain containing 3	Mus musculus	130-136
23607366-4	2013	We found that iNK T cell in-vivo cytokine responses to an iNK T cell ligand alpha-galactosylceramide (alpha-GalCer) were lower in BWF(1) mice than in non-autoimmune BALB/c and major histocompatibility complex (MHC)-matched NZB x N/B10.PL F1 mice, although iNK T cell numbers in the periphery were unchanged in BWF(1) mice compared to control mice.	alpha-galactosylceramide	76-100	WD repeat and FYVE domain containing 3	Mus musculus	310-316
15166399-3	2004	BWF1 mice, a murine model for systemic lupus erythematosus (SLE), implanted with Silastic tubes containing DES after orchidectomy developed murine lupus characterized by immunoglobulin G (IgG) anti-DNA antibody production and IgG deposition in the glomeruli in the kidney as well as those implanted with 17beta-estradiol (E2).	Diethylstilbestrol	107-110	WD repeat and FYVE domain containing 3	Mus musculus	0-4
27760209-4	2016	At week 14, the pristane-SNF1 model recapitulated kidney disease parameters and molecular signatures seen in spontaneous disease in 36 week-old SNF1 mice and in a traditional IFNalpha-accelerated NZB X NZW F1 (BWF1) model.	pristane	16-24	WD repeat and FYVE domain containing 3	Mus musculus	210-214
22002593-9	2012	Thus, a brief treatment with a CD1d-binding glycolipid enhances iNKT responses, reduces IL-10 production, and delays the onset of lupus, whereas long-term repeated treatments induce marked iNKT hyporesponsiveness and do not affect disease outcome in BWF1 mice.	Glycolipids	44-54	WD repeat and FYVE domain containing 3	Mus musculus	250-254
19660498-0	2009	A novel pseudovirus encoding Diphtheriatoxin A fragment eliminates autoantibody-producing B cells and inhibits lupus in the BWF1 mouse model.	diphtheriatoxin a	29-46	WD repeat and FYVE domain containing 3	Mus musculus	124-128
16929507-0	2007	Effects of tripterine on mRNA expression of TGF-beta1 and collagen IV expression in BW F1 mice.	celastrol	11-21	WD repeat and FYVE domain containing 3	Mus musculus	84-89